Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Multicentre, Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab in Adult Participants With Solid Tumours

NCT07391670 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT07391670
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07391670 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Multicentre, Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab in Adult Participants With Solid Tumours
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Recruiting
Start date
March 31, 2026
Completion date
August 30, 2027
Enrollment
40 (estimated)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumours